Cargando…
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer
Concomitant administration of radiotherapy with cisplatin or radiotherapy with cetuximab appear to be the treatment of choice for patients with locally advanced head and neck cancer. In the present retrospective analysis, we investigated the predictive role of several biomarkers in an unselected coh...
Autores principales: | Fountzilas, George, Kalogera-Fountzila, Anna, Lambaki, Sophia, Wirtz, Ralph M., Nikolaou, Angelos, Karayannopoulou, Georgia, Bobos, Mattheos, Kotoula, Vassiliki, Murray, Samuel, Lambropoulos, Alexandros, Aravantinos, Gerasimos, Markou, Konstantinos, Athanassiou, Eleni, Misailidou, Despina, Kalogeras, Konstantine T., Skarlos, Demosthenis |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801452/ https://www.ncbi.nlm.nih.gov/pubmed/20066159 http://dx.doi.org/10.1155/2009/305908 |
Ejemplares similares
-
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
por: Razis, Evangelia, et al.
Publicado: (2008) -
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
por: Fountzilas, George, et al.
Publicado: (2012) -
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012) -
MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
por: Gogas, Helen, et al.
Publicado: (2016) -
Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
por: Iliadis, Georgios, et al.
Publicado: (2012)